Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
暂无分享,去创建一个
Hua Yu | Domenico Coppola | Tianhong Wang | Richard Heller | D. Coppola | Hua Yu | R. Jove | M. Kortylewski | D. Pardoll | G. Niu | W. Dalton | Shumin M. Zhang | L. Burdelya | R. Heller | D. Gabrilovich | Tianhong Wang | K. Shain | R. Bhattacharya | Richard Jove | Drew Pardoll | William Dalton | Marcin Kortylewski | Kenneth Shain | Shumin Zhang | Guilian Niu | Raka Bhattacharya | Dmitry Gabrilovich | Lyudmila Burdelya
[1] S. Akira,et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.
[2] H. Schreiber,et al. Multiple tumour-specific antigens expressed on a single tumour cell , 1983, Nature.
[3] D. Pardoll,et al. CD 40-independent Pathways of T Cell Help for Priming of CD 8 1 Cytotoxic T Lymphocytes , 2000 .
[4] E. Jaffee,et al. Cancer Vaccines , 1997, Current protocols in human genetics.
[5] Hua Yu,et al. A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.
[6] P. Matzinger,et al. Is cancer dangerous to the immune system? , 1996, Seminars in immunology.
[7] L. Kanz,et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. , 2000, Cancer research.
[8] R. Locksley,et al. The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.
[9] M. Jaroszeski,et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.
[10] T. Yeatman,et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Turkson,et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.
[12] R. Jove,et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.
[13] Ira Mellman,et al. Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.
[14] R. Steinman. Inaugural Article : avoiding horror autotoxicus. The importance of dendritic cells in peripheral T cell tolerance , 2002 .
[15] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[16] C. Janeway,et al. Innate immunity: impact on the adaptive immune response. , 1997, Current opinion in immunology.
[17] Michel C. Nussenzweig,et al. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[18] Rolf M. Zinkernagel,et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.
[19] S. Akira,et al. Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.
[20] C. Meijer,et al. Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.
[21] D. Link,et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. , 2001, Immunity.
[22] D. Pardoll,et al. Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes , 2000, The Journal of experimental medicine.
[23] R. DePinho,et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.
[24] E. Jaffee,et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.
[25] J. Turkson,et al. Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.
[26] M. Kripke,et al. Mechanisms of syngeneic tumor rejection. Susceptibility of host- selected progressor variants to various immunological effector cells , 1982, The Journal of experimental medicine.
[27] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[28] C. Janeway. Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.
[29] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[30] M. Bartoli,et al. The FASEB Journal express article 10.1096/fj.02-1084fje. Published online June 17, 2003. VEGF differentially activates STAT3 in microvascular endothelial cells , 2022 .
[31] Roy Garcia,et al. STATs in oncogenesis , 2000, Oncogene.
[32] C. Uyttenhove,et al. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression , 1983, The Journal of experimental medicine.
[33] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[34] S. Rosenberg,et al. Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.
[35] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[36] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[37] J. Darnell,et al. Stat3 Recruitment by Two Distinct Ligand-induced, Tyrosine-phosphorylated Docking Sites in the Interleukin-10 Receptor Intracellular Domain* , 1996, The Journal of Biological Chemistry.
[38] J. Turkson,et al. Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.
[39] Stefania Gallucci,et al. Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.